STOCK TITAN

Farallon discloses 8.5% Crinetics stake in Schedule 13G/A (CRNX)

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Crinetics Pharmaceuticals, Inc. has a large shareholder group led by Farallon Capital Management, L.L.C., which reports beneficial ownership of 8,989,098 Shares of common stock as of June 30, 2026. This position represents 8.5% of Crinetics’ outstanding common stock.

The Shares are held across several investment partnerships collectively referred to as the Farallon Funds, for which Farallon Capital Management acts as investment manager. Multiple senior members of Farallon, including Joshua J. Dapice and Hannah E. Dunn, are listed as reporting persons with shared voting and dispositive power over 8,989,098 Shares. The Farallon Funds have the right to receive dividends and sale proceeds from these securities.

Positive

  • None.

Negative

  • None.
Shares beneficially owned 8,989,098 Shares Common Stock of Crinetics Pharmaceuticals, Inc. reported by Farallon Reporting Persons
Ownership percentage 8.5% Percent of Crinetics common stock class beneficially owned as of June 30, 2026
CUSIP 22663K107 CUSIP for Crinetics Pharmaceuticals, Inc. common stock
Date of ownership information 06/30/2026 Date associated with the reported ownership stake
beneficially owned financial
"The Shares reported hereby as <b>beneficially owned</b> by the Reporting Persons are held directly..."
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting power financial
"6 | <b>Shared Voting Power</b> 8,989,098.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power financial
"8 | <b>Shared Dispositive Power</b> 8,989,098.00"
Investment Manager financial
"Farallon Capital Management, L.L.C., the <b>Investment Manager</b>, is the investment manager..."
Schedule 13G/A regulatory
"Exhibit 1. Joint Acquisition Statement Pursuant to Section 240.13d-1(k) (<b>Schedule 13G/A</b>)"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What ownership stake in CRNX does Farallon report in this Schedule 13G/A?

Farallon and related reporting persons report beneficial ownership of 8,989,098 Shares of Crinetics Pharmaceuticals, Inc. common stock, representing 8.5% of the outstanding class as of June 30, 2026.

Who are the reporting persons in the CRNX Schedule 13G/A amendment?

The filing lists Farallon Capital Management, L.L.C. as investment manager and multiple senior members, including Joshua J. Dapice and Hannah E. Dunn, as reporting persons sharing voting and dispositive power over the Shares.

How many CRNX shares does Farallon have shared voting and dispositive power over?

Farallon Capital Management and certain individual reporting persons have shared voting power and shared dispositive power over 8,989,098 Shares of Crinetics Pharmaceuticals, Inc. common stock, according to the Schedule 13G/A.

Which entities directly hold the CRNX shares reported by Farallon?

The Shares are held by several investment partnerships known as the Farallon Funds, including Farallon Capital Partners, L.P., Farallon Capital Institutional Partners funds, Four Crossings Institutional Partners V, and multiple Cayman Islands master funds.

Who is entitled to dividends and sale proceeds from the CRNX shares?

The filing states that the Farallon Funds have the right to receive dividends and proceeds from the sale of the Crinetics Pharmaceuticals, Inc. securities beneficially owned by the reporting persons.

What is the CUSIP and class of securities reported for CRNX?

The securities are Common Stock, par value $0.001 per share of Crinetics Pharmaceuticals, Inc., with CUSIP 22663K107, as specified in the Schedule 13G/A amendment.





22663K107

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Farallon Capital Management, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member
Date:08/03/2026
Farallon Capital Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/03/2026
Farallon Capital Institutional Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/03/2026
Farallon Capital Institutional Partners II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/03/2026
Farallon Capital Institutional Partners III, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/03/2026
Four Crossings Institutional Partners V, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager of its General Partner
Date:08/03/2026
Farallon Capital Offshore Investors II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/03/2026
Farallon Capital (AM) Investors, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/03/2026
Farallon Capital F5 Master I, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager of its General Partner
Date:08/03/2026
Farallon Healthcare Partners Master, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager of its General Partner
Date:08/03/2026
Farallon Partners, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member
Date:08/03/2026
Farallon Institutional (GP) V, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager
Date:08/03/2026
Farallon F5 (GP), L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager
Date:08/03/2026
Farallon Healthcare Partners (GP), L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager
Date:08/03/2026
Dapice Joshua J.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/03/2026
Dreyfuss, Philip D.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/03/2026
Dunn Hannah E.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn
Date:08/03/2026
Gehani, Varun N.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/03/2026
Giauque, Nicolas
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/03/2026
Husen, Avner A.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/03/2026
Kim, David T.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/03/2026
Linn, Michael G.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/03/2026
Luo Patrick (Cheng)
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/03/2026
Roberts, Jr., Thomas G.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/03/2026
Saito Edric C.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/03/2026
Short Daniel S.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/03/2026
Spokes, Andrew J. M.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/03/2026
Warren, John R.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/03/2026
Wehrly, Mark C.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/03/2026
Exhibit Information

Exhibit 1. Joint Acquisition Statement Pursuant to Section 240.13d-1(k)